FOI 26-2797 – Correspondence Relating To Keytruda PD-(l)1

Written by Claude Haiku 4.5 from the extracted text on 10 Jul 2026. It can miss or misread redacted and scanned pages. Check the source before relying on it.

The PBAC (Pharmaceutical Benefits Advisory Committee) did not recommend listing pembrolizumab (Keytruda) on the PBS for unresectable advanced and metastatic cancers at its July 2025 meeting. The document outlines the formal PBAC outcome notification process, indicating that applicants with 'not recommended' decisions can pursue resubmission through designated pathways—Standard Re-entry, Early Resolution, Early Re-entry, or Facilitated Resolution—depending on PBAC assessment of additional information needed. Ratified minutes with detailed reasoning for the non-recommendation were scheduled for release on 15 August 2025, six weeks after the meeting conclusion.